Drug Trial Radar · NCT07252661
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- AccSalus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread. The purpose of this Phase 1 clinical trial is to find a safe dose of ACC-1898 and to understand how the body absorbs, distributes, and eliminates the drug (pharmacokinetics / PK). The study will also look for early signs that ACC-1898 may slow or shrink tumors and explore possible biological markers related to drug activity. Adults with advanced or metastatic solid tumors who have no remaining standard treatment options may take part. All participants will receive ACC-1898 tablets by mouth once daily in repeating 21-day cycles. Treatment may continue for up to two years if the cancer does not worsen and side effects are manageable. Safety information, laboratory results and imaging scans (CT or MRI) will be collected regularly. The study will first test different dose levels (dose-escalation phase) and may later expand enrollment in selected tumor types once a recommended dose is found.
Conditions
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Thyroid Carcinoma, Medullary
- Thyroid Carcinoma Primary Differentiated
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Melanoma
- Gall Bladder Cancer
- Advanced Solid Tumor
Interventions
ACC-1898Drug
ACC-1898 is an oral small-molecule tyrosine kinase inhibitor (TKI). Administered once daily by mouth in continuous 21-day cycles. Starting doses range from 80 mg to 300 mg QD, with possible intra-patient dose modifications. Arm(s)/Group(s): * Arm 1 - ACC-1898 Monotherapy * Arm 2 - ACC-1898 Monotherapy Route of Administration: Oral (tablet) Dose Form: Film-coated tablet (20 mg and 40 mg strengths) Treatment Duration: Up to 2 years or until disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs) Part 1 (Dose Escalation)Time frame: Cycle 1 (each cycle = 21 days)
- Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose through 28 days after last dose (up to 2 years)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.